Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting

Limited data exist comparing the safety and efficacy of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) monoinfected and HCV/human immunodeficiency virus (HIV) coinfected patients in the real-world clinic practice setting. All HCV monoinfected and HCV/HIV coinfected patients treated with...

Full description

Saved in:

Bibliographic Details
Published in:	Gut and liver Vol. 12; no. 6; pp. 694 - 703
Main Authors:	Gayam, Vijay, Hossain, Muhammad Rajib, Khalid, Mazin, Chakaraborty, Sandipan, Mukhtar, Osama, Dahal, Sumit, Mandal, Amrendra Kumar, Gill, Arshpal, Garlapati, Pavani, Ramakrishnaiah, Sreedevi, Mowyad, Khalid, Sherigar, Jagannath, Mansour, Mohammed, Mohanty, Smruti
Format:	Journal Article
Language:	English
Published:	Korea (South) Editorial Office of Gut and Liver 01-11-2018 Gastroenterology Council for Gut and Liver 거트앤리버 소화기연관학회협의회
Subjects:	Aged Antiviral Agents - administration & dosage chronic Coinfection - drug therapy Coinfection - virology direct acting antiviral agents Drug Therapy, Combination Female hcv/hiv coinfection Hepacivirus - drug effects hepatitis c Hepatitis C - drug therapy Hepatitis C - virology HIV - drug effects HIV Infections - drug therapy HIV Infections - virology Humans Male Middle Aged Original Retrospective Studies Sustained Virologic Response 내과학 HCV/HIV coinfection Sustained Virologic response Direct acting antiviral agents Hepatitis C, chronic
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Limited data exist comparing the safety and efficacy of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) monoinfected and HCV/human immunodeficiency virus (HIV) coinfected patients in the real-world clinic practice setting. All HCV monoinfected and HCV/HIV coinfected patients treated with DAAs between January 2014 and October 2017 in community clinic settings were retrospectively analyzed. Pretreatment baseline patient characteristics, treatment efficacy, factors affecting sustained virologic response at 12 weeks (SVR12) after treatment, and adverse reactions were compared between the groups. A total of 327 patients were included in the study, of which 253 were HCV monoinfected, and 74 were HCV/HIV coinfected. There was a statistically significant difference observed in SVR12 when comparing HCV monoinfection and HCV/HIV coinfection (94% and 84%, respectively, p=0.005). However, there were no significant factors identified as a predictor of a reduced response. The most common adverse effect was fatigue (27%). No significant drug interaction was observed between DAA and antiretroviral therapy. None of the patients discontinued the treatment due to adverse events. In a real-world setting, DAA regimens have lower SVR12 in HCV/HIV coinfection than in HCV monoinfection. Further studies involving a higher number of HCV/HIV coinfected patients are needed to identify real predictors of a reduced response.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1976-2283 2005-1212
DOI:	10.5009/gnl18004